



GeneTether Therapeutics Inc. Announces Third Quarter 2022 Financial Results and Reports on Corporate Highlights

Vancouver, British Columbia – November 25, 2022 – GeneTether Therapeutics Inc. (“**GeneTether**” or the “**Company**”) (CSE: GTTX), announced today the filing of its interim condensed consolidated financial statements for the period ending September 30, 2022 and reported on corporate highlights for the third quarter of fiscal 2022. GeneTether is an early-stage genetic medicine company focused on developing its disruptive proprietary GeneTether™ platform technology, which is designed to significantly increase the efficiency of DNA insertion into the genome. All dollar amounts are presented in United States dollars, unless otherwise noted. Complete financial statements along with related management and discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval, the electronic filing system for the disclosure documents of issuers across Canada, at www.SEDAR.com.

Commenting on the Company’s progress, CEO Roland Boivin said, “with global capital markets failing to exhibit any evidence of extended stability over the past several months, we continue to focus our R&D efforts on programs that can be conducted in-house. Focusing on in-house R&D allows us to preserve cash and exert greater control over experimental designs and development of protocols. In addition to our current R&D programs, we are exploring additional novel, low-cost preclinical study designs, some of which may include collaborations with third parties.”

R&D and Intellectual Property:

GeneTether continues to develop best-in-class gene editing therapies based on its proprietary GeneTether™ platform and, during the quarter ended September 30, 2022, the Company secured laboratory space in the Bay Area Disruptor and Startup Support Labs. This additional lab space enables the Company to accelerate its in-house R&D activities, which are designed to further build on the GeneTether™ platform capabilities and applications, as well as to expand the Company’s intellectual property portfolio.

Financial Results

The Company’s total assets as at September 30, 2022 were approximately \$2,248,000, including approximately \$2,009,000 in cash. Net and comprehensive loss for the quarter ended September 30, 2022 were approximately \$401,000 and \$540,000, respectively.

About GeneTether

Founded by EGB Ventures founder and managing partner, William J. Garner, M.D., and veteran gene editing researcher, R. Geoffrey Sargent, Ph.D., GeneTether is focused on developing its disruptive proprietary platform technology to significantly increase the efficiency of DNA insertion into the genome for gene correction and complementation strategies. The Company’s wholly-owned GeneTether™ platform technology uses a proprietary method to “tether” donor DNA templates to the genome editing complex, making the template readily available for use during the genome editing repair stage. The Company is leveraging its platform technology to develop curative therapies for the treatment of rare genetic diseases. GeneTether’s

proof of concept study demonstrated an approximately 7x higher gene editing efficiency as compared to the same gene editing payload without application of the GeneTether technology.

For more information, visit www.genetether.com.

Contacts:

Roland Boivin, CEO
(833) 294-4363 ext. 1
roland@genetether.com

Jean Jen, CFO and Corporate Secretary
(833) 294-4363 ext. 2
jean@genetether.com

Forward-Looking Disclaimer

This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause GeneTether's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

Forward-looking statements in this document include the expectation that the Company will continue to advance its research and development plan in-house, expectations that advancing the Company's programs in-house will help it preserve cash and enable it to exert greater control over designs and development protocols, and all other statements that are not statements of historical fact.

Although GeneTether believes the forward-looking information contained in this news release is reasonable based on information available on the date hereof, by their nature forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. By their nature, these statements involve a variety of assumptions, known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such statements.

Examples of such assumptions, risks and uncertainties include, without limitation, assumptions, risks and uncertainties associated with the global COVID-19 pandemic; general economic conditions; adverse industry events; future legislative and regulatory developments; the Company's ability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the ability of GeneTether to implement its business strategies; competition; the ability of GeneTether to obtain and retain all applicable regulatory approvals and other assumptions, risks and uncertainties, including those set forth under the heading "Risk Factors" in the Company's final prospectus dated March 21, 2022 and in the Company's subsequently filed continuous disclosure documents.

THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS NEWS RELEASE REPRESENTS THE EXPECTATIONS OF THE COMPANY AS OF THE DATE OF THIS NEWS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE THE COMPANY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS.

The Canadian Securities Exchange nor its Regulation Service has approved nor disapproved the contents of this news release